The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 19, 2026
Filed:
Jun. 26, 2020
Applicant:
Ono Pharmaceutical Co., Ltd., Osaka, JP;
Inventors:
Akio Watanabe, Osaka, JP;
Atsushi Yoshida, Osaka, JP;
Yasuo Hirooka, Osaka, JP;
Michael G. Yang, Narberth, PA (US);
Ning Li, Lexington, MA (US);
Assignee:
ONO PHARMACEUTICAL CO., LTD., Osaka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 207/34 (2006.01); A61K 31/145 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/4174 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/4965 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07C 233/76 (2006.01); C07C 323/29 (2006.01); C07D 213/56 (2006.01); C07D 213/75 (2006.01); C07D 231/12 (2006.01); C07D 233/70 (2006.01); C07D 241/18 (2006.01); C07D 401/12 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 207/34 (2013.01); A61K 31/145 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4174 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/4965 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07C 233/76 (2013.01); C07C 323/29 (2013.01); C07D 213/56 (2013.01); C07D 213/75 (2013.01); C07D 231/12 (2013.01); C07D 233/70 (2013.01); C07D 241/18 (2013.01); C07D 401/12 (2013.01); C07D 487/04 (2013.01); C07C 2601/16 (2017.05);
Abstract
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EPreceptor in the prevention and/or treatment of a disease associated with the activation of an EPreceptor, of formula (I-A): wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.